Painreform Ltd  (PRFX)
Other Ticker:  

Painreform Ltd's



PRFX Sales vs. its Competitors Q4 2022

Revenue Growth Comparisons

Net Income Comparison

<<  PRFX Stock Performance Comparisons

*Market share is calculated based on total revenue.

  News about Painreform Ltd Contracts

Revolutionary Pain Management Breakthrough: PainReform's PRF-110 Enrolls 50% in Phase 3 Clinical Trial, Top-Line Results Expected by mid-2024

In the realm of modern medicine, the ever-elusive quest for effective pain management techniques has long been a topic of intense research and development. However, PainReform, a pioneering pharmaceutical company, may be on the brink of a revolutionary breakthrough in this field. With their ground-breaking drug candidate, PRF-110, PainReform recently achieved a significant milestone, enrolling 50% of eligible participants in the second part of its phase 3 clinical trial for bunionectomy pain management. Moreover, the company is confidently on track to announce top-line data from this trial by mid-2024, signaling a potential game-changer in the field of pain management.PainReform's PRF-110, a synthetic peptid...

PRF-110: Redefining Postoperative Pain Relief with Pioneering Formulation and Extended Relief

In a groundbreaking development in the field of postoperative pain management, PainReform has recently unveiled the astounding results of their head-to-head comparison between PRF-110 and the current market-leading post-surgical analgesia. The findings not only demonstrate PRF-110's superior formulation properties but also showcase its exceptional capability of extended postoperative pain relief.Postoperative pain management has long been a significant concern for both patients and healthcare professionals. The ability to provide effective pain relief while minimizing potential side effects is crucial in improving overall patient outcomes and optimizing recovery. Recognizing this pressing need, PainReform em...

Who are Painreform Ltd's Competitors?


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com